You are here

  • Home
  • Archive
  • Volume 76, Issue 1
  • A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Bae S, Kim J, Choe J on behalf of the HERA Study Investigators, et al
A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study
Annals of the Rheumatic Diseases 2017;76:65-71.